Clinical Trial Update: Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans [Phase 1]

View source ↗

Summary

A Phase 1 safety/challenge study of the BCG TICE Bacillus Calmette-Guérin vaccine for testing tuberculosis immunity in healthy adults has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• BCG TICE(R) (Bacillus Calmette-Guérin vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Tuberculosis | Phase 1 | Status: WITHDRAWN